Clinical trial · Observational
Effect of Aromatase Inhibitors on Ultrasonographic Measurements and Static and Dynamic Balance Scores in Breast Cancer
Effect of Aromatase Inhibitors on Lower Extremity Quantitative Ultrasonographic Measurements and Static and Dynamic Balance Scores in Breast Cancer Patients Using Aromatase Inhibitors
NCT06184074CI-TRIAL-00094995completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the effects of aromatase inhibitors on lower extremity ultrasonographic measurements, static and dynamic balance scores in breast cancer patients using aromatase inhibitors
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aromatase Inhibitors | — | UNRESOLVED | — |
| Balanced | — | UNRESOLVED | — |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Breast Cancer Patients Using Aromatase Inhibitors Group
- description
- Breast cancer patients using aromatase inhibitors at least 1 year
- label
- Breast Cancer Patients Group
- description
- Breast cancer patients who have not used aromatase inhibitors before
Primary outcomes (3)
- measure
- Biodex Balance System
- timeFrame
- 5 months
- description
- We will evaluate the patients with Limit of Stability test (LOS) protocols in the biodex balance system. For these tests, the rules specified in the Biodex guide will be applied and the results will be compared between two groups
- measure
- Biodex Balance System
- timeFrame
- 20 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal Woman * Between 40-70 ages * Stage 1-3 breast cancer * Chemotherapy treatment due to breast cancer (Last dosage at least 6 months ago) * Using an aromatase inhibitors for at least 1 year for group 1 * Never using an aromatase inhibitors at all for group 2 * Volunteers must sign and agree to participate in the study. Exclusion Criteria: * Stage 4 breast cancer * Having active chemotherapy * Older age patient (over 70 years old) * Using of steroid * Presence of diabetes mellitus that lasts longer than 3 years or insulin usage * Neuropathic complaints * Lack of vitamin B12 and thyroid dysfunction * Dn4 (dolour neuropathic 4 question) score of 4 and above * History of stroke * Presence of polyneuropathy diagnosis * Medication due to polyneuropathy diagnosis (gabapentin, pregabalin, duloxetine) * Loss of motor function in the lower extremity * Use of assistive devices for walking * Presence of vestibular disorder * Presence of cognitive impairment
References
Publications (0)
Data not yet available
No reference posted for this study.